PharmTech News

Articles

INTERPHEX 2015 is under way and Pharmaceutical Technology and BioPharm International are in the middle of the action!

Highlights from INTERPHEX 2015

Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.

Teva Proposes $40 Billion to Acquire Mylan

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

WHO says that results from clinical trials should be reported within 12 months of completion of the study

WHO Pushes for Prompt Reporting and Public Disclosure of Clinical Trial Data

Pfizer announces that its Phase III trial for Ibrance met its primary endpoint and was ended early due to efficacy based on an assessment by an independent Data Monitoring Committee.

Positive Phase III Results Ends Pfizer’s Ibrance Trial Early

This is the first time a single strategy document for both EMA and HMA is presented, reflecting the need for a coordinated approach to address the challenges and opportunities facing the European regulatory system network.

EMA and HMA Reveal Network Strategy for Next Five Years

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Spending on prescription medications reached $373.9 billion in 2014, representing the largest increase in 13 years.

Study Finds Prescription Drug Spending Rose 13% in 2014

The grants will be offered to investigators conducting research in the field of PCSK9 biology.

Pfizer Announces PCSK9 Competitive Grants Program

Mylan announces that it would offer Perrigo $29 billion in cash and stock to buy the Irish company.

Mylan Offers $29 Billion for Perrigo

Novartis will make payments to Juno to settle a patent dispute covering chimeric antigen receptor T-cell (CAR-T) therapies.

Novartis and Juno Settle Over CAR-T Therapy Technology

NIH announced positive safety results from the vaccine, VSV-ZEBOV, and found that all patients in the study experienced a strong antibody response.

Top News